AstraZeneca has acquired a vaccine startup, providing the company with a simpler method for producing conjugate vaccines, according to BioPharma Dive. The report also mentions a psychedelic depression drug submission to the FDA and a sharp drop in shares for a biotech focused on autoimmune diseases.
The acquisition could influence how large pharma firms approach vaccine development and manufacturing efficiency. Senior leaders in pharma and biotech should consider how such deals may affect competitive positioning and technology adoption in vaccine pipelines.
